All In Biotech

Drug Trial Radar · NCT07570758

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess Efficacy, Safety and Tolerability of Orally Administered ERX1000 in Subjects With Obesity

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

May 28, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
ERX PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.

Conditions

  • Obesity & Overweight

Interventions

  • ERX1000Drug

    2mg tablet administered orally twice weekly.

  • PlaceboOther

    2mg Placebo tablet identical in appearance to 2mg ERX1000 tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Body Weight of Participants from Baseline to Weeks 12 and 24Time frame: From enrollment to the end of treatment at Week 24.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Monroe Biomedical Research

    Louisville, Kentucky · Recruiting

  • Monroe Biomedical Research

    Monroe, North Carolina · Recruiting

  • Monroe Biomedical Research

    North Charleston, South Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.